Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Busting Drug Discovery Bottlenecks

By Drug Discovery Trends Editor | February 7, 2013

Sources define research as “creative work undertaken systematically to increase the stock of knowledge… and the use of this stock of knowledge to devise new applications.” Although creativity demands flexibility, most software solutions that are available to drug research scientists today either:

• Limit the ability to directly compare experiments because the data is variable; or
• Constrain data analysis to processes defined prior to experimentation in order to store structured data

Drug research scientists often face the challenge of juggling their own research and analytical needs with the needs of the larger institution. Research is variable yet standardization often implies the need to conform to a process. Given these challenges, science needs a new approach for empowering scientists in drug discovery while also managing data to enable analysis across experiments.

Capturing your data
Although experimentation is typically tightly controlled to ensure scientifically relevant results, the data required to be captured and analyzed differs from experiment to experiment. Historical software solutions to this problem involved specialized data-capture mechanisms for every new procedure.  While this type of approach gives the scientist freedom in the research process, it has revealed a number of disadvantages. These include:

• Difficulty comparing results across experiments
• A lack of consistency in the interpretation of results
• Significant obstacles with sharing data

With user-definable data capture in such a structured environment, scientists are given the flexibility without sacrificing their organizational needs. Figure 1 shows an example of the free-form tables and analysis that can follow. Data appear in the interface as linked tables or spreadsheets but it is stored in a normalized table in Oracle.

For the drug researcher, the process is simple: decide what information is coming in and what information should come out. An understanding of this will define the tables and columns needed to capture data. This will also allow keep researchers from forcing unintended constraints on the experiment design.

Automated calculations, plots and curve fits can also be defined to accelerate data analysis. Scientists maintain control over the data through QC validation of results and ad hoc plotting.

Making sense of your data
Allowing scientists to define their data universe offers clear benefits but also introduces technical challenges regarding data sharing and collation. Furthermore, experimental data alone is not enough to interpret results and make informed decisions. For example, sample or compound information is often stored in a data structure separate from the results of the individual experiment but interpretation of those results typically requires merging these pieces of information together.

Many scientists spend endless time manually combining data from different data sources and transferring that data from one software platform to another. Not only does this delay reporting of experimental results but it also introduces too many possibilities for transcription errors.

Transforming and joining captured data can be facilitated through tools for adding metadata around the different types of information relevant to your research. Users indicate where key identifiers are in their experimental data (e.g., sample ID) in order to join the data with otherwise separate data sources. For example, an in vivo biologist may refer to a treatment with a compound ID. In this particular example, details for the substance being used to dose the animal exist in a separate data structure managed by a separate data entry mechanism. Having the compound ID allows the biologist to find and combine related information programmatically without the need for spreadsheet exports or complex SQL queries.

In a simpler case, where the scientist simply wants to look and aggregate across experiments—those entered by him and his colleagues—the data may be stored in the same place but is not accessible in the format required. In this situation, the data from singleton experiments can be properly merged into a comprehensive dataset and allow for a more global view. Figure 2 depicts one way to combine data across experiments into a single dataset without any need for writing code.

Discovering something new
Pre-defined reporting and charting enable scientists to quickly communicate information in a standardized format. Toxicology results for a potential drug candidate, results of an assay run and inventory usage reports are all relevant examples of defined results combined with a defined format to communicate accurate information quickly. Figure 3 shows a structure activity relationship (SAR) table, which is a traditional way of communicating biological results to the medicinal chemist.

A problem emerges when reports are the only means for data analysis. Analysis of data cannot be constrained by the methods we have used in the past. Discovering new insights hidden in results requires a level of hands-on interactivity only achievable through a dynamic data analytics platform.

Figure 4 highlights the type of chemically intelligent data portal that can be achieved when the scientist is able to define how data is visualized and interpreted. Instantaneous filtering and interactive visualizations, combined with powerful statistics, creates a fast-paced gateway to decision making.

Empowering scientists through technology leads to better science and efficient processes. This self-service solution from data capture through to analysis reduces historical bottlenecks and enables better research that bring much-needed therapies to market faster.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE